High-affinity immunoglobulin E receptor (Fc epsilon RI) bound to immunoglobulin E antibody (FcεRI–IgE complex)

The "IgE antibodies on mast cells" refers to the high-affinity binding of immunoglobulin E (IgE) antibodies to the FcεRI receptor on the surface of mast cells. IgE is produced by B cells, class switches under the influence of Th2 stimuli (e.g., IL-4), and binds its Fc region tightly to FcεRI. When a multivalent allergen cross-links bound IgE on the mast cell, it triggers cellular activation and degranulation, leading to the rapid release of histamine and other pro-inflammatory mediators responsible for allergic symptoms and anaphylaxis[1][2][4][5]. The IgE–FcεRI axis is a validated therapeutic target for allergic diseases, with multiple drugs designed to block IgE’s binding or function, thus inhibiting mast cell activation[2][5]. Targeting this axis can also downregulate FcεRI expression, reducing mast cell sensitivity[2]. Clinically, this mechanism is central in allergic asthma, rhinitis, and anaphylaxis, but it also forms part of the natural defense against parasitic infections[3][7].\n\nNote: The query target is imprecise, since it conflates the IgE antibody (a soluble molecule) with the receptor (FcεRI) and their active complex on mast cells. The canonical target in both research and therapy is the Fc epsilon receptor I (FcεRI), or the IgE–FcεRI complex on mast cells[1][2][7]. Directly targeting "IgE antibodies on mast cells" is not a standard molecular designation, hence "is_incorrect: true".

Other names

Fc epsilon receptor–IgE complexFcεRI-bound IgEIgE-FcεRI complex on mast cellImmunoglobulin E–Fc epsilon receptor

Inhibition of IgE binding to FcεRI (reduces mast cell activation); Neutralization of free IgE (prevents sensitization of mast cells); Downregulation of FcεRI surface expression